ACIU - AC Immune SA
NASDAQ
->
Healthcare
->
Biotechnology
Lausanne,
Switzerland
Type: Equity
ACIU price evolution
ACIU
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $15.67 | $0.72 | $0.98 | $0.82 |
| Inventory | ||||
| Total current assets | $125.15 | $86.18 | $99.15 | $111.69 |
| Long term investments | ||||
| Property, plant & equipment | $6.88 | $6.03 | $6.3 | $6.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $182.81 | $142.99 | $156.23 | $169.15 |
| Current liabilities | ||||
| Accounts payable | $1.68 | $1.48 | $1.35 | $1.14 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13.58 | $11.71 | $11.15 | $10.76 |
| Long term debt | $2.83 | $1.84 | $1.98 | $2.12 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.17 | $17.32 | $16.9 | $16.21 |
| Shareholders' equity | ||||
| Retained earnings | -$316.2 | -$310.49 | -$296.06 | -$280.11 |
| Other shareholder equity | -$0.05 | $0.01 | -$0.01 | $0 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $82.22 | $160.89 | ||
| Short term investments | $116 | $65 | ||
| Net receivables | $15.67 | $0.8 | $1.4 | $1.9 |
| Inventory | ||||
| Total current assets | $125.15 | $128.09 | $202.63 | $231.77 |
| Long term investments | ||||
| Property, plant & equipment | $6.88 | $7.07 | $8.03 | $6.64 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $7.44 | |||
| Total investments | ||||
| Total assets | $182.81 | $185.94 | $261.44 | $238.74 |
| Current liabilities | ||||
| Accounts payable | $1.68 | $0.93 | $2 | $2.18 |
| Deferred revenue | $0.33 | |||
| Short long term debt | ||||
| Total current liabilities | $13.58 | $11.48 | $20.03 | $14.02 |
| Long term debt | $2.83 | $2.25 | $2.34 | $1.8 |
| Total noncurrent liabilities | $9.86 | |||
| Total debt | ||||
| Total liabilities | $22.17 | $16.95 | $29.46 | $23.26 |
| Shareholders' equity | ||||
| Retained earnings | -$316.2 | -$264.01 | -$200.94 | -$132.85 |
| Other shareholder equity | -$0.05 | $0.01 | -$0.11 | |
| Total shareholder equity | $231.98 | $215.48 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $15.47 | $17.05 | $17.57 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $0 | $0 | |
| Interest expense | $0.33 | $0.22 | $0.06 | |
| Net income | ||||
| Net income | -$15.14 | -$16.83 | -$17.51 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.8 | $3.94 | $15.43 | |
| Cost of revenue | $62.28 | $59.49 | ||
| Gross Profit | -$62.28 | -$44.06 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $17.91 | $18.56 | ||
| Total operating expenses | $68.42 | $74.78 | $79.01 | $76.69 |
| Operating income | -$79.01 | -$61.26 | ||
| Income from continuing operations | ||||
| EBIT | -$79.01 | -$61.26 | ||
| Income tax expense | $0.01 | $0.01 | $0 | |
| Interest expense | -$0.6 | $0.11 | -$0.58 | -$0.18 |
| Net income | ||||
| Net income | -$54.23 | -$70.75 | -$73 | -$61.92 |
| Income (for common shares) | -$73 | -$61.92 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $65.64 | $42.37 | $37.65 | $42.8 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $43.25 | $2.22 | $1.77 | -$0.14 |
| Effect of exchange rate | -$1.58 | -$0.03 | -$0.08 | -$0.01 |
| Change in cash and equivalents | $46.91 | $0.34 | $8.42 | $25.85 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$73 | -$61.92 | ||
| Operating activities | ||||
| Depreciation | $2.41 | $1.97 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$65.69 | -$59.52 | ||
| Investing activities | ||||
| Capital expenditures | -$2.63 | -$1.71 | ||
| Investments | -$51 | $30 | ||
| Total cash flows from investing | $65.64 | $23.76 | -$53.66 | $28.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $22.95 | -$0.95 | ||
| Total cash flows from financing | $43.25 | -$1.35 | $40.75 | -$0.8 |
| Effect of exchange rate | -$1.58 | $0.52 | -$0.07 | -$0.7 |
| Change in cash and equivalents | $46.91 | -$50.63 | -$78.68 | -$32.69 |
News
Fundamentals
| Market cap | $234.11M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 99.20M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.22 |
| Quick ratio | N/A |